Abstract Purpose: Glutathione S-transferases (GST) are xenobiotic metabolizing enzymes involved in the detoxification of a variety of chemotherapeutic drugs, including platinum derivatives. Genetic polymorphisms of GSTs have been associated with enzyme activity variations. Thus, a study was done to investigate the relationship between GST polymorphisms and oxaliplatin-related cumulative neuropathy in gastrointestinal cancer patients treated with oxaliplatin-based chemotherapy. Experimental Design: Ninety patients were included. Clinical neurologic evaluation was done at baseline and before each cycle of treatment.We determined genetic variants for GSTP1 exon 5 (Ile   105 Val), GSTP1 exon 6 (Ala 114 Val), GSTM1 (homozygous deletion), and GSTT1 (homozygous deletion). We conducted analyses in a subgroup of 64 patients receiving a minimal cumulative dose of 500 mg/m 2 of oxaliplatin to examine whether the GST polymorphisms are associated with oxaliplatin-related cumulative neuropathy. Results: Among patients receiving a minimal cumulative dose of 500 mg/m 2 of oxaliplatin, 15 patients showed clinically evident oxaliplatin-related cumulative neuropathy scored grade 3 according to an oxaliplatin-specific scale. The oxaliplatin-related cumulative neuropathy scored grade 3 was significantly more frequent in patients homozygous for the GSTP1 105 Ile allele than in patients homozygous or heterozygous for the GSTP1
Pharmacogenetics is becoming an increasingly important field in the study of cancer chemotherapy treatment. Genetic factors affecting the metabolism and transport of drugs partly explain interindividual variability in drug response, both in terms of efficacy and safety. Polymorphisms in genes encoding specific drug-metabolizing enzymes can result in individuals in the general population being characterized as low, rapid, or even ultrarapid metabolizers. Phenotyping and genotyping tests are now available to determine and predict the metabolic status of an individual and, thus, enabling the evaluation of risk of treatment failure or toxicity.
Currently, oxaliplatin is one of the most frequently used chemotherapy agent used in the palliative treatment of gastrointestinal cancers and, more recently, in the adjuvant treatment of colorectal cancer. The dose-limiting side effect of oxaliplatin is a cumulative peripheral neuropathy usually observed after 4 to 6 months of treatment (1 -3) . The oxaliplatininduced cumulative neuropathy is often a cause for dose reduction or treatment discontinuation. Approximately 10% to 18% of patients develop oxaliplatin-induced cumulative neuropathy progressively when a cumulative dose of 800 mg/m 2 is reached (4) . Because oxaliplatin-induced neurotoxicity causes significant discomfort, alters patient quality of life, and may be accompanied by significant disability, effort could be made to optimize oxaliplatin-based chemotherapy.
Glutathione S-transferases (GST) are a multigene family of enzymes (cytosolic and membrane-bound), which catalyze the conjugation of glutathione to electrophilic xenobiotics to inactivate them and facilitate their excretion from the body (5) . GSTs play an important role in the metabolism of potentially genotoxic compounds by preventing of DNA damage and adduct formation. The cytosolic isoenzymes are divided at least into five major classes (a, A, k, u,~) among which genetic polymorphisms have been detected in the genes encoding GSTM3, GSTM1 (A class), GSTT1 (u class), GSTP1 (k class), and GSTZ1 (GST~class; refs. 6 -8) . Among them, the GSTM1, GSTT1, and GSTP1 genotypes have been extensively studied for their potential modulating role in individual susceptibility to cancer or drug response (8 -10) . Growing evidence indicates that GST enzymes determine cytotoxicity of a variety of chemotherapeutic drugs (11 -18) . The isoenzyme GSTP1 participates in the detoxification of platinum derivatives, especially cisplatin, and is an important mediator of both intrinsic and acquired resistance to platinum. In addition to GSTP1, the activity of GSTM1 and GSTT1 could be involved in the response to treatment (19) . However, the role of these enzymes specifically in the oxaliplatin pathway remains unknown.
Genetic variations of GSTs have been associated with changes in enzyme activity. Four common polymorphisms in the GSTP1, GSTT1, and GSTM1 genes either decrease or abolish GST enzyme activity. GSTP1 is a polymorphic gene located on chromosome 11 with two single-nucleotide substitutions in exon 5 (A313G) and exon 6 (C341T) that give rise to Ile 105 Val and Ala 114 Val amino acid substitutions, respectively (6) . These amino acid substitutions seem to be within the GSTP1 active site and lead to the alteration of substrate affinity (5, 6, 20, 21) .
By contrast, inherited homozygous deletion of GSTT1 or GSTM1 gene leads to a complete absence of enzymatic activity. To date, in spite of the biochemical evidence that the GSTs mediate inactivation of platinum drugs, the association between polymorphisms in the GST genes and the neurotoxicity of these compounds remains to be explored. This prompted us to evaluate the different GSTP1, GSTT1, and GSTM1 genetic polymorphisms as predictive factors for the oxaliplatin-induced neuropathy in 64 patients receiving a minimal cumulative dose of 500 mg/m 2 of oxaliplatin.
Patients and Methods
Patients. From January 2002 to September 2004, 90 adult patients (52 men, 38 women; mean age, 64 years; range, 24-84 years) with gastrointestinal solid tumors who received an oxaliplatin-based chemotherapy were included in this retrospective analysis. This study was conducted in one medical center. All patients entered in this study signed an informed consent form for blood sample collection to establish the clinical significance of genetic polymorphisms in gastrointestinal cancer. Because the aim of this study was to determine whether genetic polymorphisms may be predictive of cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy, we enrolled only patients who received a minimal cumulative dose of 500 mg/m 2 of oxaliplatin. The patients with neuropathy or who received platinum-based chemotherapy before oxaliplatin-based chemotherapy were excluded. Among the 90 patients who participated in this study, 64 patients received a minimal cumulative dose of 500 mg/m 2 oxaliplatin and were eligible for the analysis. In the group of nonenrolled patients receiving lesser than 500 mg/m 2 , no grade 3 neuropathy was observed. The characteristics of eligible patients are summarized in Table 1 . All tumors were classified as adenocarcinoma. Fifty-two patients with stage IV colorectal cancer received palliative oxaliplatin-based chemotherapy as first-line in 39 cases and as secondline in 13 cases. The palliative treatments were semimonthly regimens of 5-fluorouracil, leucovorin, and oxaliplatin previously described: FOLFOX4 regimen (oxaliplatin 85 mg/m 2 ), n = 38; FOLFOX7 regimen (oxaliplatin 130 mg/m 2 ), n = 7; FOLFOX6 regimen (oxaliplatin 100 mg/m 2 ), n = 6 (22 -24) . One patient received oxaliplatin combined with raltitrexed as previously described (TOMOX; 25). Six patients with stage III colorectal cancer received adjuvant oxaliplatin-based chemotherapy (FOLFOX4 regimen). Six patients with other gastrointestinal cancer received palliative oxaliplatin-based chemotherapy. The treatments as first-line chemotherapy were as follows: oxaliplatin combined with gemcitabine as previously described (GEMOX), n = 4; FOLFOX4 regimen, n = 2 (26) . Physical examination and a full blood count were done before each cycle. The same chemotherapy regimen was maintained until disease progression or severe toxicity. Cumulative oxaliplatin-induced neuropathy was scored according to the oxaliplatin-specific scale reported by Caussanel et al. (27) . On this oxaliplatin-specific scale, the grade of cumulative neuropathy depends on the duration and intensity of symptoms (grade 1: paresthesia, dysesthesia of short duration; grade 2: paresthesia, dysesthesia persisting between cycles; grade 3: paresthesia, dysesthesia causing functional impairment).
DNA extraction. The genomic DNA was purified from peripheral lymphocytes using a commercial kit (QiAmp Blood DNA kit, Qiagen, Courtaboeuf, France) and stored at À20jC until use.
PCR. The DNA samples (10-50 ng/AL) were analyzed using the PCR. All the PCR analyses were done using a reaction volume of 25 AL GSTM1, GSTT1, and exon 5 GSTP1 genotyping. The GSTM1, GSTT1, and GSTP1 genotypes were determined by a slightly modified method previously described (21, 28) . This method allows the simultaneous genotyping of all three GSTs in the same tube. Briefly, a multiplex PCR was conducted using primer pairs specific to each GST gene (28) . The fragment lengths of the PCR products were 480 bp for GSTT1, 215 bp for GSTM1, and 176 bp for GSTP1. The presence of the GSTM1 or GSTT1 gene generated positive PCR signals, whereas the deletion did not. The results were validated using the GSTP1 PCR fragment as an internal amplification control. The PCR product was then subjected to restriction fragment analysis using BsmAI enzyme (New England Biolabs, Saint Quentin en Yvelines, France). Only the 176 bp GSTP1 fragment was cut into 91 and 85 bp fragments when the GSTP1
105
Val allele was present and not cut when the GSTP1 105 Ile allele was present. The digestion products were revealed in a polyacrylamide (8%) gel electrophoresis.
Genotyping of exon 6 GSTP1 polymorphism. The polymorphism Ala 114 Val located in exon 6 was detected by use of a 5 ¶ nuclease allelic discrimination assay (ABI PRISM 7700 Sequence Detection System; Applied Biosystems, Foster City, CA). The SNP (National Center for Biotechnology Information Reference rs1799811) was identified based on the TaqMan Drug Metabolism Genotyping Assay (commercially available, Applied Biosystems), in the conditions recommended by the manufacturer.
Statistical analysis. The primary end point was the development of a grade 3 cumulative neuropathy to oxaliplatin. For quantitative variables, the cutoff level chosen was the median value. For qualitative variables, patients were grouped according to the presence or absence of each variable. The Mann-Whitney test was used to compare the means of two independent groups. GSTP1, GSTT1, and GSTM1 polymorphisms were analyzed separately to evaluate the association between the polymorphisms and cumulative neuropathy to oxaliplatin. The m 2 test was used to compare the observed genotype distributions with those expected by the Hardy-Weinberg equilibrium. m 2 or Fisher's twotailed exact test was used to determine the relationship between cumulative neuropathy to oxaliplatin with the GSTT1, GSTP1, and GSTM1 genotypes. Furthermore, the two GSTP1 genotypes were combined to define four haplotypes. GSTP1*A has Ile at codon 105 and Ala at codon 114. GSTP1*B has Val at codon 105 and Ala at codon 114. GSTP1*C has both Val at codon 105 and 114, and GSTP1*D has Ile at position 105 and Val at position 114. We grouped the patients homozygous for *A/*A and tested them against the others. Associations were quantified by calculating odds ratios (OR) with profile likehoodbased 95% confidence intervals (95% CI). The calculation of ORs and 95% CIs was adjusted for potential confounding factors (i.e., age, gender, and treatment protocol). Second, multiple logistic regression analysis was applied to adjust ORs for these potential confounding factors. The probability of survival without grade 3 neuropathy during oxaliplatin-based chemotherapy was estimated using the methods of Kaplan and Meier (29) . The comparison of survival without grade 3 neuropathy during oxaliplatin-based chemotherapy for patients with or without GSTP1
105 Val allele was done by log-rank test. The log-rank test was stratified according to the treatment protocol (i.e., FOLFOX4 regimen versus other regimens). All statistical tests were two-sided, and P < 0.05 was used to indicate statistical significance.
Results
In the group of eligible patients, a total of 680 cycles was administered (median, 10 per patient); the median dose- ) in those without (Mann-Whitney test, P = 0.9). There are no significant differences between the group of patients who developed grade 3 cumulative peripheral neuropathy to oxaliplatin and those without in terms of age, gender, and chemotherapy regimen (Table 2) .
Genotype data for the GSTP1 exon 5 and GSTT1 polymorphisms were available for all 64 eligible patients, whereas data were available for 63 patients for the GSTP1 exon 6 and GSTM1 polymorphisms ( (5, 30) . The distribution of the exon 6 GSTP1 genotype was 90% for the Ala/Ala genotype (57 patients; 95% CI, 80-96%) and 10% for the Ala/Val genotype (6 patients; 95% CI, 4-20%). The above distribution is in close agreement with that predicted by the HardyWeinberg equilibrium (m 2 = 0.16, P = 0.7). The observed frequency for GSTP1 114 Val was 0.047 (6 of 126) and was similar to previous reports on allele frequencies for healthy Caucasians and for colorectal cancer patients (5, 30). When we combined these two genotypes, 38 (62.3%) patients were *A/*A homozygous, 18 were *A/*B heterozygous (29.5%), 1 was *B/*B homozygous (1.7%), and 4 were *B/*C heterozygous (6.5%). The haplotypes cannot be unambiguously deduced in two patients because they were heterozygous for both 105 and 114 polymorphisms and they are possibly *A/*C or *B/*D. The frequencies of the GSTT1 and GSTM1 homozygous gene deletions were 0.23 (i.e., 15 of 64 patients had homozygous deletions of GSTT1) and 0.57 (i.e., 36 of 63 patients had homozygous deletions of GSTM1), respectively. Eleven patients (17.5%) showed a homozygous deletion of both genes.
Grade 3 cumulative peripheral neuropathy was significantly more common in patients with Ile/Ile GSTP1 exon 5 genotype (13 of 39 patients, 33%) compared with patients with Ile/Val or Val/Val GSTP1 exon 5 genotype (2 of 25 patients, 8%; m 2 = 5.45, P = 0.02; Table 4 ). As a result, patients who were genotyped as Ile/Ile GSTP1 exon 5 had a higher risk of developing a grade 3 cumulative peripheral neuropathy to oxaliplatin than did those with other GSTP1 exon 5 genotypes (unadjusted OR, 5.75; 95% CI, 1.08-30.74; P = 0.02). Research.
on July 20, 2017. © 2006 American Association for Cancer clincancerres.aacrjournals.org Downloaded from Our sample size of 63 patients combined with the distribution of GSTP1 haplotypes over the four categories did not allow a reasonable, matched assessment of the association of GSTP1 haplotypes with risk of neuropathy grade 3. However, we compared patients homozygous for the *A/*A haplotype to the others. The ORs for GSTP1*A/GSTP1*A category compared with the non-GSTP1*A/GSTP1*A category was 5.3 (P =0.03). The same significant association was observed when we adjusted our analysis by age (dichotomized on the median age of all the patients), gender, and chemotherapy regimen (FOLFOX4 regimen versus other regimens; Table 5 ). When logistic regression analysis was applied, it was found that GSTP1*A/GSTP1*A haplotype was significantly associated with the risk of developing a grade 3 cumulative peripheral neuropathy to oxaliplatin (adjusted OR, 5.54; 95% CI, 1.1-28.02; P = 0.03; Table 6 The patients with non-GSTP1*A/GSTP1*A haplotypes had a significantly better survival without grade 3 neuropathy during oxaliplatin-based chemotherapy than the ones with GSTP1*A/ GSTP1*A haplotype (Fig. 1) . The 30 weeks probability of survival without grade 3 neuropathy during oxaliplatin-based chemotherapy for patients with GSTP1*A/GSTP1*A haplotype was 0.42 (95% CI, 0.11-0.64), compared with 0.92 (95%CI, 0.64-0.97) for patients without GSTP1*A/GSTP1*A haplotype (P = 0.048 by the log-rank test stratified according to the chemotherapy regimen).
Discussion
In the present study, we investigated whether the determination of common polymorphisms in GSTP1, GSTT1, and GSTM1 genes in gastrointestinal cancer patients who received oxaliplatin-based chemotherapy could be used to predict the occurrence of oxaliplatin-related cumulative neuropathy. Our results suggest that a relevant polymorphism of GSTP1 gene can modulate the risk of severe neuropathy among gastrointestinal cancer patients who received oxaliplatin-based chemotherapy. This is the first study reporting an association between a GSTP1 genetic polymorphism and oxaliplatin-related cumulative neuropathy.
Neurotoxicity is the main and dose-limiting toxicity of oxaliplatin, with two distinct syndromes. First, a unique syndrome of acute neurosensory toxicity is generally triggered and exacerbated by exposure to cold (31) . This acute neurotoxicity of oxaliplatin is associated with abnormal function of voltage-gated potassium channels in peripheral nerves and characterized by peripheral-nerve hyperexcitability (32) . Second, long-term administration of oxaliplatin produces a sensory neuropathy, with loss of sensation and dysesthesias in the distal extremities. Development of sensory neuropathy is correlated with the cumulative dose of oxaliplatin and is most commonly seen in patients who have received total doses z540 mg/m 2 (33) . For instance, in one randomized study, grade 3 neurotoxicity was observed in 18% of patients, and the estimated incidence of severe neuropathy, with a dose of 85 mg/m 2 per cycle, was 10% after nine cycles, 25% after 12 cycles, and 50% after 14 cycles (1). In our study, the incidence of grade 3 oxaliplatin-related neuropathy was similar to previous reports.
On cessation of drug, the chronic neurotoxicity recovers in the majority of patients within 4 to 6 months and will completely resolve in f40% of patients by 6 to 8 months (34, 35) . Table 3 . Distribution of GSTM1, GSTT1, and GSTP1 genotypes and GSTP1 haplotypes The mechanism of platinum-induced neurotoxicity has been proposed to involve the accumulation of platinum within the peripheral nerve system (36, 37). The major site of damage is likely the dorsal root ganglia, consistent with the platinum accumulation studies; it results in axonopathy of peripheral nerves, especially in the large myelinated fibers responsible for sensory nerve conduction (37, 38) . Table 4 . Distribution of GSTM1, GSTT1, GSTP1 exons 5 and 6 genotypes and GSTP1 haplotypes based on analysis of a dichotomous trait (with and without grade 3 cumulative neuropathy to oxaliplatin) Oxaliplatin-induced chronic neuropathy is a growing, relevant clinical problem because, actually, use of oxaliplatin is expanding (a) in metastatic colorectal cancer as well as in the adjuvant setting, as indicated by the results of MOSAIC trial and (b) in several other cancers (1 -3) . Only one previous unpublished report has studied the association between GSTP1 and GSTM1 genotypes and oxaliplatin-related cumulative neuropathy. In a series of patients with advanced colorectal cancer treated with an oxaliplatin-based chemotherapy, McLeod et al. (39) did not find an association between GSTP1 and GSTM1 genotypes and the severity of oxaliplatin-related cumulative neuropathy. The analysis limited to the patients who received an oxliplatin minimal cumulative dose of 500 mg/m 2 is likely more efficient to evidence the role of GSTP1 genotypes in the occurrence of a severe neuropathy, because under this dose the frequency of neuropathy is very low.
In our study, the GSTP1
105
Ile allele was significantly more frequent in patients with grade 3 cumulative peripheral neuropathy. GSTP1 belongs to a multigene family of enzymes that catalyze the conjugation of glutathione to electrophilic molecules to inactivate them and facilitate their excretion (40) .
Previous studies revealed that the Ile 105 Val substitution modify the substrate affinity of the GSTP1 enzyme. Individuals homozygous for the GSTP1
Val genotype had an altered catalytic activity depending on substrates compared with individuals homozygous for the GSTP1 105 Ile allele (5, 41). In particular, there is in vitro evidence that GSTP1 105 Val allele alone or in combination with the GSTP1 114 Val allele are much more active than the wild-type alleles against cisplatin and carboplatin (42). Thus, the increase rate of grade 3 neuropathy in patients homozygous for GSTP1 *A/*A haplotype could be explained by the diminished capacity of detoxifying oxaliplatin. The involvement of GSTP1 in cellular apoptosis could be another hypothesis to explain the protective effect of the variant genotype. Indeed, the role of GSTP1 in cellular defense was recently proposed as a consequence of its ability to interact with c-Jun NH 2 -terminal kinase (JNK). Adler et al. (43) have shown that GSTP1 is an inhibitor of the stress-inducible JNK and has also a role in regulating of the constitutive expression of target genes of the JNK signaling pathway, in particular when containing an activator protein-1 binding site. The absence of GSTP1 protein in GSTP1/P2 À/À mice results in increased constitutive JNK activity leading to the up-regulation of specific downstream genes implicated in antioxidant cellular response (44 -46) . The GSTP-null mice are therefore highly resistant to the hepatotoxic effects of acetaminophen and we hypothesized that the patients carrying GSTP1
Val allele are similarly protected against cumulative peripheral neuropathy to oxaliplatin (45) . Recently, Wang et al. (47) have shown that d-JNKI-1, a JNK inhibitor, potentiates the ototoxic effects of cisplatin, suggesting that this pathway is important in protecting against toxicity of this compound. In cells treated with cisplatin, the activation of JNK is necessary for caspase activation and apoptosis induction. It has also been showed that cisplatin induces activator protein-1 DNA binding activity (48) . Altogether, the following hypothesis can be put forward: The GSTP1 105 Ile protein could enhance oxaliplatin neurotoxicity through its inhibition of JNK, whereas the GSTP1 105 Val protein allows a higher activity of JNK, inducing the expression of genes involved in cellular defense and, thus, protecting the cells against platinum toxicity.
As the use of oxaliplatin becomes established in the treatment of colorectal cancer both as palliative or adjuvant chemotherapy, it is important to determine the predictive factors of neurotoxicity to this agent. Our study had several limitations. First, we evaluated only a relatively small number of patients. Second, patients received different oxaliplatin-based chemotherapies. Therefore, our data should be considered as preliminary results and more large studies with identical oxaliplatin-based chemotherapy are need to confirm that the GSTP1 genotype may be a powerful predictor of cumulative neuropathy to oxaliplatin-based chemotherapy. This finding could be provide the opportunity for safer chemotherapy for patients with gastrointestinal cancer requiring oxaliplatin-based treatment, and raises the possibility of being able to individualize the oxaliplatin dose by the identification of patients requiring monitoring or adjustment. Thus, this genotyping may be useful to prevent or limit the oxaliplatin-induced cumulative neuropathy. Fig. 1 . Probability of survival without grade 3 neuropathy during oxaliplatin-based chemotherapy by GSTP1haplotypes. P is calculated by log-rank adjusted according to the chemotherapy regimen. 
